



## **For immediate release**

Seinäjoki, Finland 10.07.2024

THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS NOT INTENDED TO BE PUBLISHED, DISCLOSED, OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, CANADA, SINGAPORE, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

## **Eevia publishes the outcome of the rights issue**

Eevia Health Plc ("Eevia" or "the Company") today announces the outcome of the rights issue for which the subscription period ended on June 28, 2024, in Sweden and on July 2, 2024, in Finland (the "Rights Issue" or "Offer"). A total of 28,360,404 shares, corresponding to 59.6 percent of the shares in the Offer, have been allocated. Current shareholders subscribed for 18,629,364 shares (39.1 percent) with subscription rights. Current and new shareholders subscribed for another 9,731,040 shares (20.4 percent) without subscription rights. In total, investors subscribed for 59.6 percent of the Rights Issue. A total of 7,090,096 warrants of series TO1 will be issued. Through the Rights Issue, the Company will raise proceeds of approximately SEK 17.0 million before deducting costs related to the Rights Issue. The Rights issue did not utilize any guarantee commitments.

*"I'm grateful for the vote of confidence in our Company from our current and new investors. The rights issue funds are essential pillars in our financial growth plan. Eevia plans to take advantage of several great market opportunities. The board and the management team focus on our financial targets and revenue growth. I look forward to communicating our progress with you going forward."* - says Stein Ulve, CEO at Eevia.

### **About the Rights Issue**

Existing shareholders provided subscription commitments, and external investors provided guarantee undertakings for the Rights Issue, guaranteeing up to 50.2 percent of the Rights issue, but the Rights issue did not utilize any of these guarantee commitments. Through the Rights Issue, the Company will raise approximately SEK 17.0 million before deduction of costs related to the Rights Issue, which are estimated to approximately SEK 2.5 million.

The net proceeds from the Rights Issue are primarily planned to increase the Company's working capital and repay a short-term bridge loan of SEK 7.5 million plus interest, which the Company acquired in May 2024. Improved working capital will enable the Company to handle growth in customer receivables. Eevia will also increase its focus on developing the organization to facilitate continued growth.

### **Delivery of shares**

Eevia expects the shares in the Offer to be registered with the Finnish Trade Register (the "Trade Register") approximately on or about July 22, 2024. The Company further expects the delivery of the shares in the Offer to the subscribers in the Offer through Euroclear Finland approximately on or about July 23, 2024, and Euroclear Sweden approximately on or about July 31, 2024. The shares of the Company are registered in the electronic book-entry securities system maintained by Euroclear Finland. The Company and its shares will have their primary registration in the book-entry register of Euroclear Finland. Further, the shares are registered in the corresponding Swedish book-entry securities system maintained by Euroclear Sweden.



Eevia will announce the last day of trading with Paid Subscribed Shares (Sw. BTA) and the first day of trading for the new shares as soon as the Rights Issue is registered with the Finnish Trade Register.

#### **Dilution**

The number of shares in Eevia will increase by 28,360,404 shares from 35,713,884 shares to 64,074,288 shares, implying a dilution of 44.3 percent for existing shareholders who do not participate in the Offer.

#### **Advisor**

Partner Fondkommission is the financial adviser and issuer agent in connection with the Offer in Sweden, and OP Bank is the issuer agent in Finland.

#### **For more information, please contact:**

Stein Ulve, CEO, Eevia Health Plc

Joel Westerström, Partner Fondkommission

Email: [stein.ulve@eeviahealth.com](mailto:stein.ulve@eeviahealth.com)

Email: [joel.westerstrom@partnerfk.se](mailto:joel.westerstrom@partnerfk.se)

Telephone: +358 400 22 5967

Telephone: +46 735 11 68 53

*This information is such that Eevia Health Plc is required to make it public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on July 10, 2024, at 13:00 CET.*

#### **INFORMATION ABOUT EEVIA HEALTH PLC**

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health manufactures 100% organically certified plant extracts. Our commitment to sustainable and organic manufacturing practices, such as wild harvesting our raw materials and operating a modern green chemistry production facility, ensures the highest quality products for our customers.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name EEVIA (<https://spotlightstockmarket.com/en/companies/irabout?InstrumentId=XSAT000085FD>).

To learn more, please visit [www.eeviahealth.com](http://www.eeviahealth.com) or follow Eevia Health on LinkedIn @EeviaHealth.

#### **IMPORTANT INFORMATION ABOUT THE PRESS RELEASE AND DOCUMENTS**

This press release does not constitute an offer to acquire, subscribe to, or otherwise trade in shares, subscription rights, paid subscription shares, or other securities in Eevia Health Plc. Investors must subscribe to or acquire securities only based on the information in the IM. No action has been taken, and no action will be taken to permit an offer to the public in any jurisdiction other than Sweden.



This press release must not be published or distributed, directly or indirectly, to or within Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the US, or any other jurisdiction where the distribution of this press release is against the law. Similarly, this press release does not constitute an offer to sell new shares, paid subscription shares, subscription rights, or other securities to anyone in a jurisdiction where it is not allowed to make such an offer to such a person or where such action would require an additional prospectus, registration, or measures other than those required under Swedish law. The IM, registration slip, and other documents attributable to the Rights Issue may not be distributed to or within any country where such distribution or Rights Issue requires measures as stated in the preceding sentence or where this would contravene the law of that country.

No shares, subscription rights, paid subscription shares, or other securities have been registered or will be registered pursuant to the 1933 United States Securities Act in its current version ("the Securities Act") or securities legislation in any state or other jurisdiction of the US, and may not be offered, subscribed to, utilized, pledged, sold, resold, granted, supplied, or otherwise transferred, directly or indirectly, to or within the US, except in accordance with any applicable exemption from or by a transaction that is not covered by the registration requirements of the Securities Act and in accordance with the securities legislation in the relevant state or other jurisdiction of the US.